Carlos A. Zepeda

Carlos A. Zepeda has worked in the pharmaceutical industry since 2006. Carlos A. began their career as a Research Chemist at SIGNA S.A. DE C.V., where they developed and optimized synthetic processes for production of Mesalamine (anti-inflammatory), Acyclovir (anti-viral), and Midodrene (drug precursor). Carlos A. then moved into a Project Manager role, where they assisted the regulatory team by managing the R&D drug master file information and the dossier for different generic products, resulting in successful FDA filings for Acyclovir and Valsartan. Carlos A. also led a team of seven process chemists focused on the optimization of commercial manufacturing processes. From 2014 to 2021, Carlos worked at the Ontario Institute for Cancer Research as a Research Scientist and Postdoctoral Fellow. During this time, they designed compounds with clear hypotheses for improved potency, selectivity, functional activity and ADME/PK properties, and supported the development of a selective serine/threonine-protein kinase inhibitor for cancer immunotherapy. Carlos A. also played a role in the screening to hit-identification phase of novel undrugged therapeutic targets with the objective of generating chemical probes in collaboration with the Structural Genomic Consortium (SGC) and other academic partners, producing one chemical probe and seven publications. Carlos is currently working as a Principal Scientist I, Group Leader at the Treventis Corporation.

Carlos A. Zepeda has a Doctor of Philosophy (Ph.D.) in Organic Chemistry from McMaster University, a Bachelor's Degree in Medicinal and Pharmaceutical Chemistry from Universidad La Salle, A.C., and a Master's Degree in Organic Chemistry from Universidad Nacional Autónoma de México.